Tsai S Y, Schillinger K, Ye X
Department of Molecular and Cellular Biology, One Baylor Plaza, Houston, TX 77030, USA.
Curr Opin Mol Ther. 2000 Oct;2(5):515-23.
The past several years have seen significant progress in the development of adenoviral vectors with markedly decreased pathological potential and greatly increased capacity for incorporation of foreign DNA. Paralleling these developments in gene transfer technology have been remarkable advances in both the design and optimization of gene regulatory systems. Ultimately, the goal of these gene regulatory systems is control of transgene expression in vivo by the administration of an exogenous compound. With the prospect of clinical human gene therapy on the horizon, the co-evolution of safe and efficient gene transfer strategies, with effective regulation of transgene expression, represents an essential step towards therapeutically viable gene transfer protocols. This review introduces recent advances in both adenoviral-based vectors and gene regulatory systems, and examines those studies in which adenoviral vectors and gene-regulatory systems have been combined in vivo.
在过去几年中，腺病毒载体的开发取得了显著进展，其病理潜力显著降低，外源DNA的掺入能力大大提高。与基因转移技术的这些发展相平行的是，基因调控系统的设计和优化也取得了显著进展。最终，这些基因调控系统的目标是通过施用外源化合物来控制体内转基因的表达。随着临床人类基因治疗前景的临近，安全有效的基因转移策略与转基因表达的有效调控共同发展，是迈向具有治疗可行性的基因转移方案的关键一步。本文综述了基于腺病毒的载体和基因调控系统的最新进展，并考察了那些在体内将腺病毒载体与基因调控系统相结合的研究。
